American Capital Advisory’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.9K Buy
275
+13
+5% +$1.09K 0.01% 287
2026
Q1
$21K Buy
262
+3
+1% +$247 0.01% 283
2025
Q4
$22.1K Buy
259
+4
+2% +$328 0.01% 277
2025
Q3
$19.8K Hold
255
0.01% 269
2025
Q2
$19.9K Buy
255
+10
+4% +$746 0.01% 264
2025
Q1
$17.8K Buy
245
+5
+2% +$358 0.01% 267
2024
Q4
$17.8K Hold
240
0.01% 264
2024
Q3
$15.8K Hold
240
0.01% 262
2024
Q2
$18.3K Buy
+240
New +$21.3K 0.01% 226
2024
Q1
Sell
-240
Closed -$18.3K 482
2023
Q4
$18.3K Buy
+240
New +$16.7K 0.01% 226

Other funds holding EW

American Capital Advisory's EW Position: Q2 2026 in Review

American Capital Advisory increased its Edwards Lifesciences (EW) stake by 5% in Q2 2026, buying an estimated $1.09K and bringing the position to 275 shares worth $24.9K. The position accounts for 0.01% of the portfolio, ranked #287.

American Capital Advisory first reported a position in EW in Q4 2023 and has held it in 10 quarters since. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • American Capital Advisory held 275 shares of Edwards Lifesciences worth $24.9K as of Q2 2026.
  • American Capital Advisory bought 13 Edwards Lifesciences shares in Q2 2026, an estimated $1.09K.
  • Edwards Lifesciences made up 0.01% of American Capital Advisory's portfolio in Q2 2026, its #287 holding.
  • American Capital Advisory first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 10 quarters since.
  • 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.